Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Laguens
Martin Laguens, La Plata AR
| Patent application number | Description | Published |
|---|---|---|
| 20080279958 | SNAKE VENOM COMPOSITIONS AND METHODS OF USE - The invention relates to the discovery that formulations of Lachesis venom decrease circulating TNF-α levels in mammals including humans, and that administration of Lachesis venom-containing formulations to mammals suffering from sepsis, parasitic infection, cisplatin nephrotoxicity, rheumatoid arthritis, cancer and AIDS mitigates symptoms associated with these conditions. | 11-13-2008 |
Rubén Laguens, Buenos Aires AR
| Patent application number | Description | Published |
|---|---|---|
| 20090275645 | METHOD TO INDUCE NEOVASCULAR FORMATION AND TISSUE REGENERATION - The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium. | 11-05-2009 |
Rubén Laguens, Buenos Aires AR
| Patent application number | Description | Published |
|---|---|---|
| 20090275645 | METHOD TO INDUCE NEOVASCULAR FORMATION AND TISSUE REGENERATION - The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium. | 11-05-2009 |
Ruben P. Laguens, La Plata AR
| Patent application number | Description | Published |
|---|---|---|
| 20080279958 | SNAKE VENOM COMPOSITIONS AND METHODS OF USE - The invention relates to the discovery that formulations of Lachesis venom decrease circulating TNF-α levels in mammals including humans, and that administration of Lachesis venom-containing formulations to mammals suffering from sepsis, parasitic infection, cisplatin nephrotoxicity, rheumatoid arthritis, cancer and AIDS mitigates symptoms associated with these conditions. | 11-13-2008 |